

## Remarks

### Amendments to the Claims

The amendments to claims 81, 85, 89, 92, 93, and 96, and the addition of claims 97 and 98 were described in Applicants' amendment filed January 26, 2007. Because the Patent Office did not enter these amendments, Applicants again present these claims as "currently amended" or "new."

Claims 99-105 are newly presented in this paper. Claim 99 recites that the modified HA protein comprises an alteration at the HA protein cleavage site. The specification supports claim 99 at page 51, lines 3-5.

Claim 100 recites that the composition of claim 99 is formulated as a vaccine. Claim 101 recites that the composition of claim 96 is formulated as a vaccine. The specification supports claims 100 and 101 at page 50, lines 4-6.

Claim 102 recites that the vaccine of claim 100 is suitable for intranasal administration. Claim 103 recites that the vaccine of claim 101 is suitable for intranasal administration. The specification supports claims 102 and 103 at page 52, lines 15-19.

Claim 104 recites that the virus particles of any of claims 81, 85, 89, 92, 93, or 99 are killed. Claim 105 recites that the composition of claim 104 is formulated as a vaccine. The specification supports claims 104 and 105 at page 51, lines 20-22.

The originally-filed application supports these amendments. Because a Request for Continued Examination accompanies this paper, entry of the amendments is respectfully requested.

Conclusion

Applicants respectfully submit that the remarks and amendments filed in responses dated January 26, 2007 and October 12, 2007 to the final Office Action mailed September 11, 2006 place the application in condition for allowance. Entry of these remarks and amendments is respectfully requested.

Respectfully submitted,

Date October 12, 2007

  
**Michelle Holmes-Son** (47,660)  
**MedImmune, Inc.**  
One MedImmune Way  
Gaithersburg, MD 20878  
Telephone: 301-398-5765